Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
395 Enhancement of bispecific T cell engagers (bispecific TCE) killing potency in AML with the neximmune artificial immune modulation (AIM™) adoptive cell therapy (ACT) T cells
Compose a Response to This Article
Other responses
No responses have been published for this article.